FORM 4

obligations may continue. See

Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

BENEFICIAL OWNERSHIP

STATEMENT OF CHANGES IN	l
-------------------------	---

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Kelly Lisa (First) (Middle)							VERTEX PHARMACEUTICALS INC / MA [VRTX]								all applicable) Director Officer (give title below)		10% Ow Other (sp below)		wner
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 07/12/2011									S	VP, Huma	n Re	sources	
130 WAVERLY ST (Street) CAMBRIDGE MA 02139					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Indiv ne) X	[']				
(City)	(S	tate)	(Zip)																
		Tab	le I - N	lon-Deri	vativ	e Sec	uriti	es A	cquire	d, D	isposed o	f, or B	eneficia	lly	Owned				
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/N						Execution Date,			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			Benefic		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) or (D)	Price	Transaction (Instr. 3 and		tion(s)			(111501. 4)
Common Stock 07/12/20					2011	11		М		953	A	\$28.8	4	39,035		D			
Common Stock 07/12/20					2011	11		S ⁽¹⁾		953	D	\$51.22	(2)(3) 38,		3,082		D		
Common Stock															1,	520		I	401(k)
		1	Table II								posed of, converti			y O	wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	med on Date, Day/Year)	4. Transa Code (8)		on of		6. Date Exercis Expiration Dat (Month/Day/Ye		te	7. Title a Amount Securitie Underly Derivatie (Instr. 3	of es ing ve Security	De Se (Ir	Price of erivative ecurity istr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	i ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or Number of Shares	ber					
Stock	\$28.84	07/12/2011			М			953	10/12/2	007(4)	07/11/2017	Commo	053		\$0.00	954	T	D	

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Ms.\ Kelly-Croswell's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Open market sales reported on this line occurred at a weighted average price of \$51.22 (range \$50.21 to \$51.56).
- 3. Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Right to buy under 2006 Stock and Option Plan vesting in 16 quarterly installments from 07/12/2007.

Remarks:

Valerie L. Andrews, Attorney-

07/13/2011

In-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.